Eisai (ESALY) News Today → Trump convicted... now what? (From Stansberry Research) (Ad) Free ESALY Stock Alerts $61.51 -1.33 (-2.11%) (As of 01/30/2023) Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 7 at 2:06 AM | americanbankingnews.comHead to Head Review: Eisai (OTCMKTS:ESALY) versus EVN (OTCMKTS:EVNVY)March 29, 2024 | wsj.comEisai Co. Ltd. ADRMarch 23, 2024 | reuters.comEisai Co LtdMarch 20, 2024 | morningstar.comEisai Co Ltd 4523February 15, 2024 | finance.yahoo.comBIIB Mar 2024 210.000 callFebruary 15, 2024 | finance.yahoo.comBIIB Feb 2024 227.500 callFebruary 15, 2024 | finance.yahoo.comBIIB Mar 2024 235.000 callFebruary 14, 2024 | finance.yahoo.comBIIB Mar 2024 205.000 putJanuary 12, 2024 | seekingalpha.comESALF Eisai Co., Ltd.December 8, 2023 | markets.businessinsider.comMerck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet EndpointsSeptember 25, 2023 | msn.comJapan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment LeqembiSeptember 22, 2023 | msn.comMerck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung CancerJuly 10, 2023 | marketbeat.comBiogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi (ESALY)Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.July 6, 2023 | markets.businessinsider.comFDA Grants Traditional Approval To Eisai's Leqembi To Treat Adult Patients With Alzheimer's DiseaseJune 13, 2023 | benzinga.comAlzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare ResourcesJune 11, 2023 | markets.businessinsider.comFDA Panel Recommends Full Approval For Biogen And Eisai's Alzheimer's Drug LeqembiJune 8, 2023 | msn.comBernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'January 9, 2023 | finance.yahoo.comUTHR or ESALY: Which Is the Better Value Stock Right Now?January 6, 2023 | finance.yahoo.comFDA approves treatment for people with mild forms of Alzheimer’sNovember 30, 2022 | finance.yahoo.comDespite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's CandidateNovember 30, 2022 | seekingalpha.comBiogen rallies Alzheimer’s drug developers after full data for lecanemabNovember 30, 2022 | finance.yahoo.comOpen Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer'sNovember 30, 2022 | seekingalpha.comBiogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swellingNovember 30, 2022 | barrons.comBiogen and Eisai’s Alzheimer’s Data Confirm Benefit. Questions Still Loom.November 28, 2022 | seekingalpha.comBiogen drops after report on second death linked to Alzheimer’s candidateNovember 28, 2022 | finance.yahoo.comUTHR vs. ESALY: Which Stock Is the Better Value Option?November 17, 2022 | msn.comAfter Rallying 50% in the Last 2 Months, Is Biogen Stock Still a Buy?November 15, 2022 | finance.yahoo.comRoche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate LingersNovember 2, 2022 | marketbeat.comFY2024 Earnings Estimate for Eisai Co., Ltd. (OTCMKTS:ESALY) Issued By Jefferies Financial GroupEisai Co., Ltd. (OTCMKTS:ESALY - Get Rating) - Equities research analysts at Jefferies Financial Group dropped their FY2024 earnings estimates for Eisai in a research report issued on Sunday, October 30th. Jefferies Financial Group analyst S. Barker now forecasts that the company will post earninOctober 29, 2022 | msn.comPatient Death in Alzheimer's Study May Limit Drug's ReachOctober 18, 2022 | seekingalpha.comBiogen Alzheimer’s data de-risked beta amyloid hypothesis - Roche executiveOctober 18, 2022 | finance.yahoo.comDespite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say ResearchersSeptember 29, 2022 | investing.comBiogen shares soar on landmark Alzheimer's data, lift rivalsSeptember 28, 2022 | seekingalpha.comMany Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai dataSeptember 28, 2022 | finance.yahoo.comThis Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS ApprovalSeptember 28, 2022 | markets.businessinsider.com2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug DataSeptember 28, 2022 | investing.comAnalysis-Alzheimer's drug breakthrough big boost for Roche, Eli LillySeptember 28, 2022 | seekingalpha.comBiogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trialSeptember 28, 2022 | realmoney.thestreet.comBiogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks GameSeptember 28, 2022 | msn.comIs This the First Alzheimer's Drug to Actually Work?September 28, 2022 | investing.comEisai says Alzheimer's drug succeeds in slowing cognitive declineSeptember 28, 2022 | seekingalpha.comBiogen, Eisai Alzheimer's candidate lecanemab meets primary endpoint in late-stage trialSeptember 27, 2022 | barrons.comPharmaceutical Makers Eisai and Biogen Claim Success in Latest Alzheimer’s Drug TrialSeptember 24, 2022 | fool.comEisai Co., Ltd (ADR) (OTC: ESALY)September 23, 2022 | barrons.comCan We Beat Alzheimer’s? Biogen and Eisai’s Latest Drug Trial Will Offer Clues.September 18, 2022 | seekingalpha.comESALY Eisai Co., Ltd.September 12, 2022 | finance.yahoo.comMerck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver CancerAugust 16, 2022 | investing.comEisai Co., Ltd. (4523)August 6, 2022 | seekingalpha.comEisai Co., Ltd. (ESALY) Management on Q1 2023 Results - Earnings Call TranscriptAugust 6, 2022 | markets.businessinsider.comEisai is about to announce its earnings — here's what to expect Get Eisai News Delivered to You Automatically Sign up to receive the latest news and ratings for ESALY and its competitors with MarketBeat's FREE daily newsletter. Email Address Time is Running Out - June 25th Deadline Approaching! (Ad)Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry. That will slam shut June 25. ESALY Media Mentions By Week ESALY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESALY News Sentiment▼0.000.76▲Average Medical News Sentiment ESALY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESALY Articles This Week▼10▲ESALY Articles Average Week Get Eisai News Delivered to You Automatically Sign up to receive the latest news and ratings for ESALY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ITOCY News Today MURGY News Today KDDIY News Today BAMXF News Today BMWYY News Today BCMXY News Today BAESY News Today DNZOY News Today CMPGY News Today OLCLY News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ESALY) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTime is Running Out - June 25th Deadline Approaching!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored